Lantheus (NASDAQ:LNTH) had its price target raised by analysts at Truist Financial Corporation from $80.00 to $82.00. They now have a "buy" rating on the stock.
Lantheus (NASDAQ:LNTH) had its price target raised by analysts at Mizuho from $60.00 to $72.00. They now have an "outperform" rating on the stock.
Ratio Therapeutics has Successfully Dosed the First Cohort in its Phase 1/2 Study Evaluating a Novel FAP-Targeted Radiopharmaceutical in Patients with Late-Stage Aggressive Sarcomas [Yahoo! Finance]
Reassessing Lantheus Holdings After Recent Share Price Volatility and Cash Flow Outlook [Yahoo! Finance]
Lantheus (LNTH) Valuation Revisited After Truist Upgrade on Double-Digit Growth Potential [Yahoo! Finance]